Northwest Biotherapeutics (NWBO) Free Cash Flow (2010 - 2026)
Northwest Biotherapeutics (NWBO) posted quarterly Free Cash Flow of -$12.6 million for Q1 2026, down 32.88% year-over-year from -$18.8 million in Q1 2025, and up 19.34% quarter-over-quarter from -$15.7 million in Q4 2025.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Free Cash Flow (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$12.6 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 32.88% year-over-year to -$12.6 million; the TTM figure through Mar 2026 stood at -$49.4 million (up 10.02% YoY), while the FY2025 annual figure was -$46.3 million, up 20.27% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$12.6 million, up from -$15.7 million in the prior quarter.
- The five-year high for Free Cash Flow was -$7.0 million in Q2 2025, with the low at -$20.3 million in Q4 2024.
- The 5-year median for Free Cash Flow is -$13.0 million (2022), against an average of -$13.5 million.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow sank 83.75% in 2022, then jumped 58.18% in 2025.
- Northwest Biotherapeutics' Free Cash Flow stood at -$11.0 million in 2022, then sank by 57.83% to -$17.4 million in 2023, then dropped by 16.59% to -$20.3 million in 2024, then rose by 22.66% to -$15.7 million in 2025, then climbed by 19.34% to -$12.6 million in 2026.
- Business Quant data shows NWBO's Free Cash Flow at -$12.6 million in Q1 2026, -$15.7 million in Q4 2025, and -$14.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | -7.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.37 Mn |
| Mar 31, 2026 | -12.64 Mn |
| Dec 31, 2025 | -15.67 Mn |
| Sep 30, 2025 | -14.10 Mn |
| Jun 30, 2025 | -6.99 Mn |
| Mar 31, 2025 | -9.51 Mn |
| Dec 31, 2024 | -20.26 Mn |
| Sep 30, 2024 | -8.41 Mn |
| Jun 30, 2024 | -16.72 Mn |
| Mar 31, 2024 | -12.65 Mn |
| Dec 31, 2023 | -17.38 Mn |
| Sep 30, 2023 | -14.36 Mn |
| Jun 30, 2023 | -12.77 Mn |
| Mar 31, 2023 | -12.57 Mn |
| Dec 31, 2022 | -11.01 Mn |
| Sep 30, 2022 | -16.39 Mn |
| Jun 30, 2022 | -15.25 Mn |
| Mar 31, 2022 | -13.03 Mn |
| Dec 31, 2021 | -12.80 Mn |
| Sep 30, 2021 | -9.70 Mn |